BPC-157

The evidence base is animal and cell-culture work, not human outcome data. Sport Integrity Australia states plainly that BPC-157 "is not approved for human use", that the multiple preclinical studies of it in conditions such as inflammatory bowel disease and soft tissue injury were not conducted in humans, and that "there are currently no studies investigating BPC-157's use in human subjects". Healthy Male, an Australian government-funded men's health body, describes "a concerning lack of published clinical trial data" and characterises the only human data as one very small, low-quality study in 16 participants with knee pain and no control group. Note the two sources differ slightly on whether any human study exists at all, which is itself a signal of how thin the literature is. There is no randomised controlled trial of BPC-157 for any longevity or healthspan outcome, and no human data on lifespan, biological ageing, or any ageing biomarker. Safety is genuinely unknown rather than merely unstudied: Healthy Male notes "there is not enough evidence of its safety", and Sport Integrity Australia flags that pathways associated with BPC-157 have been linked to tumour growth, cardiovascular disease, and neurodegenerative disease, though this is mechanistic concern rather than demonstrated human harm. Product quality is a further risk, with warnings that online products may differ from their label or be contaminated. In short, a real preclinical signal for tissue repair is being sold as a longevity intervention that no human evidence supports.

What it is

Plain-language explainer

Categories

Common questions

What is BPC-157?

The evidence base is animal and cell-culture work, not human outcome data. Sport Integrity Australia states plainly that BPC-157 "is not approved for human use", that the multiple preclinical studies of it in conditions such as inflammatory bowel disease and soft tissue injury were not conducted in humans, and that "there are currently no studies investigating BPC-157's use in human subjects". Healthy Male, an Australian government-funded men's health body, describes "a concerning lack of published clinical trial data" and characterises the only human data as one very small, low-quality study in 16 participants with knee pain and no control group. Note the two sources differ slightly on whether any human study exists at all, which is itself a signal of how thin the literature is. There is no randomised controlled trial of BPC-157 for any longevity or healthspan outcome, and no human data on lifespan, biological ageing, or any ageing biomarker. Safety is genuinely unknown rather than merely unstudied: Healthy Male notes "there is not enough evidence of its safety", and Sport Integrity Australia flags that pathways associated with BPC-157 have been linked to tumour growth, cardiovascular disease, and neurodegenerative disease, though this is mechanistic concern rather than demonstrated human harm. Product quality is a further risk, with warnings that online products may differ from their label or be contaminated. In short, a real preclinical signal for tissue repair is being sold as a longevity intervention that no human evidence supports.

How strong is the evidence for BPC-157?

Commercial. It is offered and sold, which is a statement about availability, not about efficacy.

Is BPC-157 approved in Singapore?

variis has no Health Sciences Authority position on file for BPC-157. Absence of a recorded position is not approval.

Is BPC-157 approved in Australia?

Therapeutic Goods Administration position on record: Not approved by the TGA and not listed on the Australian Register of Therapeutic Goods (ARTG), per Sport Integrity Australia. Separately, BPC-157 is a Schedule 4 (prescription only) substance under the Poisons Standard, so it is illegal to possess without a valid prescription from a registered Australian practitioner. The TGA's own notice of final decisions for ACMS #43 (published 22 May 2024) lists BPC-157 among the substances decided on, confirming the scheduling action, though the exact entry wording and date of effect sit in a linked PDF that could not be retrieved. Because it is not on the ARTG, any clinical supply is as an unapproved therapeutic good, in practice as a compounded preparation dispensed by an Australian pharmacy against a prescription. It is also prohibited at all times in sport under WADA Prohibited List category S0 (Non-Approved Substances), and Sport Integrity Australia states a Therapeutic Use Exemption "would not be granted for the use of BPC-157, in any medical condition". A reported March 2025 rescheduling could not be verified against a TGA source and is not asserted here.. An evidence grade and a regulatory approval are different questions.

Which clinics offer BPC-157?

1 clinic in the variis directory across Singapore and Australia has BPC-157 on record. Each is listed on this page with its own sourced profile.

What else is BPC-157 called?

Also known as BPC157, Body Protection Compound 157, Body Protective Compound 157, pentadecapeptide BPC 157, Bepecin, PL 14736, PL-10, PLD-116.